
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is supported by a credible clinical and regulatory inflection point, as Revita met its six-month REMAIN-1 co-primary endpoint with statistically significant weight-regain reduction versus sham (p=0.0023), while participants retained about 80% of GLP-1-induced weight loss and the company targets a late 4Q26 FDA De Novo submission. The durability story is strengthened by REVEAL-1 one-year data showing 78% weight-loss retention, 100% responder performance on the ≥5% maintenance threshold, and no late device-related adverse events, which should help de-risk adoption and reimbursement. Financially, management’s 45% workforce reduction and refocus on Revita are expected to cut quarterly operating cash spending by about 50% to $8 million by the end of 2Q27, preserving runway into 2Q27 while key 1Q27 and 3Q26 data milestones approach.
Bears say
Fractyl Health is burdened by a highly speculative clinical-stage profile, with its valuation dependent on the projected chances of success of Revita and Rejuva rather than any established commercial revenue base. The company faces material binary risks, including failed or inconclusive clinical trials, uncertainty around adding new assets from its platforms, and the possibility that promising data may never translate into approvable therapies. Its financial downside is amplified by the need for adequate funding to advance development, creating exposure to dilutive capital raises and even delisting risk if exchange compliance is not maintained.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Fractyl Health Inc (GUTS) Forecast
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares